DOSAGE INDEX / SINGLE
GHK-Cu
Research, reported schedules and supply planning.
Examine GHK-Cu wound models, the human laser-resurfacing trial, skin penetration research and injectable safety concerns using original sources.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 1–2 mg per administration; alternative example uses 2 mg
- Frequency
- Five days weekly; alternative three times weekly
- Cycle / observation period
- 12 weeks or longer in the source
- Route / research model
- Subcutaneous
Titration & progression
The phases below describe the named source example, not an instruction to increase a dose. Product-label schedules and research examples are identified separately.
| Phase | Amount per administration | Frequency |
|---|---|---|
| Days 1–28 | 1 mg | 5 days per week |
| Days 29–56 | 1.5 mg | 5 days per week |
| Days 57–84 | 2 mg | 5 days per week |
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
Source example: 84-day planning window: 90 mg total material. Use this total below, or enter a different documented total for comparison.
| Vial strength | Vials needed |
|---|---|
| 50 mg | 2 |
| 100 mg | 1 |
Calculated from the displayed schedule.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- Maquart and colleagues implanted wound chambers in rats and compared local GHK-Cu exposure with controls. They reported increased accumulation of extracellular-matrix components, including collagen and glycosaminoglycans, in the chamber contents. [1]
- Parker and colleagues studied topical GHK-Cu after creating skin flaps in previously irradiated rats. Thirteen treated and ten control animals were assessed after ten days. Using the study's significance threshold of P below .01, the investigators concluded that the assessed ischemia, vessel and VEGF outcomes did not differ significantly. [2]
- A randomized study compared post-CO2-laser skin regimens with or without GHK-Cu. Thirteen patients completed the study. Blinded and computer-based assessments did not find an advantage for earlier redness resolution, wrinkles or overall skin quality. A patient questionnaire favored the GHK-Cu regimen for perceived overall skin improvement, with P = .04. [3]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 30 entries mapped from 2 source pages. Medical and supporting references are retained below; supplier entries are excluded.
- Maquart 1993, rat wound chambers
- Parker 2013, irradiated rat flaps
- Miller 2006, post-laser skin-care trial
- Hostynek 2010, isolated-skin penetration study
- FDA injectable GHK-Cu safety context
- Mulder GD, et al. Wound Repair and Regeneration. Human diabetic-ulcer study of topical glycyl-L-histidyl-L-lysine copper.Further reading · Listed in reference bibliography.
- Abdulghani AA, et al. 1998. Comparative topical-cream study including a copper-binding peptide preparation.Further reading · Listed in reference bibliography.
- Badenhorst T, et al. 2016. Split-face GHK-Cu nano-serum study of collagen, elastin, and wrinkle-related outcomes.Further reading · Listed in reference bibliography.
- Hostynek JJ, et al. Inflammation Research. 2010. Final human-skin penetration paper for a GHK-Cu preparation.Further reading · Listed in reference bibliography.
- Pickart L, Margolina A. International Journal of Molecular Sciences. 2018. Review of regenerative and gene-expression research involving GHK-Cu.Further reading · Listed in reference bibliography.
- Maquart FX, et al. 2000. GHK-related modulation of matrix metalloproteinase-2 expression.Further reading · Listed in reference bibliography.
- ClinicalTrials.gov. NCT07437586. Ongoing Phase 2 study of topical GHK-Cu gel for acute skin-wound healing.Trial registry · Listed in reference bibliography.
- U.S. Food and Drug Administration. 503A Categories Update. Route-specific bulk-substance evaluation context for GHK-Cu.Regulatory / product information · Listed in reference bibliography.
- U.S. Food and Drug Administration. 510(k) K953853. Iamin Gel topical wound-dressing device record.Regulatory / product information · Listed in reference bibliography.
- Roswell Park Comprehensive Cancer Center. General self-injection preparation, site rotation, and disposal guidance.Further reading · Listed in reference bibliography.
- Centers for Disease Control and Prevention. Current subcutaneous injection technique job aid.General guidance · Listed in reference bibliography.
- World Health Organization, NCBI Bookshelf. Best practices for injections and related procedures.Further reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.